Publication

[Journal of Hematology & Oncology] Researchers tested the ability of growth arrest-specific protein 6 (GAS6) based CAR-T-cell to kill pancreatic cancer cell both in vitro and in vivo, and futher evaluated its safety in mice and nonhuman primates.

[ACS Nano] Investigators developed an all-in-one biomimetic mineralized CRISPR/Cas9 RNA delivery system, that allowed for precise control over the coencapsulation ratio between Cas9 mRNA and multiple sgRNAs, while also exhibiting a high RNA loading capacity.

[Science Advances] Scientists performed single-cell RNA sequencing and mass cytometry to study the heterogeneity of CAR-natural killer (NK) cells and their in vivo evolution after adoptive transfer, from the phase of tumor control to relapse.

[Immunology] Researchers explored whether flap structure-specific endonuclease 1 (FEN1) inhibitors combined with CAR-T-cell immunotherapy would have a stronger killing effect on solid tumors.

[Molecular Therapy Oncolytics] Investigators demonstrated that nanobody-derived bispecific CAR-T cells significantly improved anti-tumor efficacy in T-lymphoma treatment.

[Molecular Cancer Therapeutics] In vivo efficacy and safety studies using NSG mice and the high-grade serous ovarian cancer cell line OVCAR4 demonstrated a remarkable and specific anti-tumor response at all the CAR-T cell doses used.